TGF-β signaling pathway

The Transforming Growth Factor-beta (TGF-β) pathway is a pleiotropic cytokine-signaling system that controls cell proliferation, differentiation, apoptosis, and extracellular matrix production across virtually all metazoan tissues. In aging biology, TGF-β occupies a central position as a paracrine suppressor of adult stem cell activity: elevated TGF-β1/3 ligand levels in aged systemic circulation impair satellite cell activation and hippocampal neurogenesis, directly contributing to the stem-cell-exhaustion hallmark. The pathway also mediates the pro-fibrotic and immunosuppressive arms of the aging secretome, intersecting with altered-intercellular-communication.

Naming note: The pathway page uses the bare wikilink [[tgf-beta]]. Individual TGF-β superfamily ligand proteins (TGFB1, TGFB2, TGFB3, gdf11, gdf15, myostatin/GDF8) will be seeded separately under molecules/proteins/. The bmp-signaling pathway (BMP sub-family) is a sibling pathway within the broader TGF-β superfamily and has its own page.

Identity and canonical database entries

Field	Value
KEGG	hsa04350 — “TGF-beta signaling pathway - Homo sapiens”
Reactome	R-HSA-170834 — “Signaling by TGF-beta Receptor Complex”
WikiPathways	WP366 (human)
Superfamily	TGF-β superfamily (~33 human ligands including BMPs, Activins, GDFs, AMH, Nodal)
Core ligands covered here	TGF-β1, TGF-β2, TGF-β3 (TGFB1/2/3 genes)

Canonical (SMAD-dependent) signaling

Step-by-step mechanism

Ligand secretion and activation. TGF-β ligands are secreted in a latent form associated with the Latency-Associated Peptide (LAP) and Latent TGF-β Binding Proteins (LTBPs). Extracellular activation (by proteases, integrins, or reactive oxygen species) releases the mature dimer.
Receptor engagement. The active TGF-β dimer binds the constitutively active Type II receptor kinase (TβRII, encoded by TGFBR2). TβRII then recruits and transphosphorylates the Type I receptor (TβRI, most commonly ALK5, encoded by TGFBR1) at the GS domain, activating its kinase ¹.
R-SMAD phosphorylation. Activated ALK5 directly phosphorylates the C-terminal SXS motif of the receptor-regulated SMADs SMAD2 and SMAD3, converting them from a monomeric, latent state to an activated form capable of forming heteromeric complexes ¹.
SMAD complex formation. Phosphorylated SMAD2/3 associates with the co-SMAD SMAD4 to form a trimeric complex. This complex translocates to the nucleus.
Transcriptional regulation. The SMAD2/3:SMAD4 trimer binds SMAD-binding elements (SBEs; 5’-GTCT/AGAC-3’) in promoters of target genes, often cooperating with context-dependent transcription factors (AP-1, FoxO, RUNX). Canonical target genes include CDKN1A (p21), SERPINE1 (PAI-1), CTGF, and SNAIL (in EMT contexts).

I-SMAD negative feedback

SMAD7 (an inhibitory SMAD, I-SMAD) is itself a TGF-β target gene, forming a direct negative feedback loop:

SMAD7 competes with SMAD2/3 for binding to activated TβRI, blocking R-SMAD phosphorylation ¹.
SMAD7 recruits the E3 ubiquitin ligases SMURF1/SMURF2 to the receptor complex, triggering receptor ubiquitination and proteasomal degradation.
SMAD6 (the other I-SMAD) primarily inhibits BMP/SMAD1/5/8 signaling and has a less prominent role in TGF-β/SMAD2/3 regulation.

Non-canonical (SMAD-independent) signaling

TGF-β activates multiple non-SMAD branches, often in a cell-type- and context-dependent manner ¹:

Branch	Key effectors	Functional consequence
MAPK/ERK	RAS → RAF → MEK → ERK	Proliferation, migration; interacts with EMT
JNK/p38 MAPK	TAK1 (MAP3K7) → MKK4/7 → JNK; TAK1 → MKK3/6 → p38	Apoptosis, stress response
PI3K/AKT	PI3K → AKT → mTORC1	Cell survival, protein synthesis; intersects mtor and pi3k-akt-pathway
Rho-ROCK	Rho GTPases → ROCK → actin remodeling	Cytoskeletal reorganization, EMT

Non-canonical branches often mediate the pro-oncogenic effects of TGF-β in late-stage tumors (see Cancer section), whereas the canonical SMAD branch drives tumor-suppressive and senescence-inducing effects in early contexts.

Aging biology

TGF-β signaling is emerging as one of the key pathways mediating the paracrine suppression of tissue regeneration by the aged systemic environment. Two primary mechanisms have been identified: (1) elevated circulating TGF-β1 directly suppresses stem cell niches, and (2) SASP-driven TGF-β acts locally to propagate cell-cycle arrest and stem cell dysfunction.

Heterochronic parabiosis and aged satellite cells

The foundational evidence that the systemic environment — not intrinsic stem cell aging — is the proximate cause of age-related satellite cell dysfunction comes from heterochronic parabiosis experiments: when aged mice share circulation with young partners, aged satellite cell activation is restored ².

Carlson et al. (2008) — the foundational mechanistic paper — identified pSMAD3 as the primary elevated species in aged satellite cells and showed that pSMAD3 drives induction of CDK inhibitors (p15, p16, p21, p27) which lock satellite cells in a non-responsive quiescence; Notch signaling normally antagonizes this by restricting pSMAD3 access to CDK inhibitor promoters ³. Carlson and Conboy (2009) followed this work to dissect the relative contributions of TGF-β vs Wnt in aged satellite cell niches, and showed that pharmacological inhibition of TGF-β receptor signaling restores satellite cell proliferation in aged muscle ⁴. Together these establish elevated TGF-β/pSMAD3 as a key driver of the regenerative deficit in aged skeletal muscle, operating through SMAD3-dependent transcription of cell-cycle inhibitor target genes. See smad2-smad3 for the molecular detail of pSMAD3 chromatin access and Notch antagonism.

Dimension	Status
Pathway conserved in humans?	yes
Phenotype conserved in humans?	yes (muscle regenerative capacity declines with age in humans)
Replicated in humans?	in-progress — no direct pharmacological intervention trial yet in aged human muscle

needs-human-replication — TGF-β receptor inhibition has not been tested for muscle regeneration in humans. needs-replication — The mechanistic sufficiency of pSMAD3 elevation (versus other elevated inhibitory signals in aged niches) is based on single-lab studies.

TGF-β1 elevation in aged systemic milieu and neurogenesis

Yousef et al. (2015) demonstrated that systemic attenuation of TGF-β signaling using the small-molecule TβRI/II inhibitor SB505124 simultaneously rejuvenated hippocampal neurogenesis and muscle satellite cell function in aged mice, supporting the idea that elevated circulating TGF-β acts broadly across stem cell niches ⁵.

Dimension	Status
Pathway conserved in humans?	yes
Phenotype conserved in humans?	partial (neurogenesis declines with age in humans but the degree is debated)
Replicated in humans?	no

needs-human-replication contradictory-evidence — The extent of adult hippocampal neurogenesis in humans is itself contested, complicating translation of this finding.

SASP-TGF-β crosstalk and senescence propagation

Senescent cells (see cellular-senescence and sasp) secrete TGF-β1/2/3 as part of the SASP. This creates a paracrine mechanism by which senescent cells suppress the proliferation of neighboring stem and progenitor cells via SMAD2/3 activation, contributing to tissue-level regenerative failure. TGF-β-mediated bystander senescence — where SMAD2/3-activated cells upregulate p21 and arrest — may amplify senescent burden with age. no-mechanism — the relative contribution of autocrine vs. paracrine TGF-β loops in tissue aging has not been quantified in vivo.

GDF family members in aging

Several TGF-β superfamily members beyond TGF-β1/2/3 are aging-relevant:

gdf11 (GDF11, BMP-11) — Controversial claim that declining GDF11 in aged blood contributes to aging phenotypes; independent labs have disputed the parabiosis interpretation. See gdf11 for full evidence assessment.
Myostatin (GDF8) — Anti-myogenic; limits skeletal muscle growth. Expression increases relative to muscle mass with aging; myostatin inhibition enhances muscle mass in aged mice. Closely tied to sarcopenia. needs-human-replication — myostatin inhibitor trials in aged humans have had mixed results.
gdf15 — Stress-responsive cytokine; elevated in aging and disease contexts; potential biomarker of mitochondrial stress. See gdf15 page.

TGF-β in cancer: dual-edge biology

TGF-β displays a well-characterized context-dependent switch from tumor-suppressive to tumor-promoting activity across cancer progression ⁶:

Early tumors: tumor suppression

Cell-cycle arrest. SMAD3/4 transcriptional complexes induce CDKN1A (p21) and CDKN2B (p15^INK4B^), suppressing G1/S transition.
Apoptosis induction. In epithelial cells, TGF-β can induce apoptosis via BIM upregulation and BCL-2 family modulation.
Loss of TGF-β responsiveness is among the most common events in carcinogenesis — SMAD4 homozygous deletion occurs in ~50% of pancreatic cancers; TGFBR2 frameshift mutations occur in colorectal cancers with microsatellite instability.

Late tumors: pro-metastatic

Epithelial-to-mesenchymal transition (EMT). Non-canonical MAPK/Rho branches plus SNAIL/TWIST transcription factors dismantle epithelial junctions and drive invasiveness.
Immune evasion. TGF-β suppresses NK cell cytotoxicity, inhibits CD8+ T cell activation, and promotes regulatory T cell differentiation — creating an immunosuppressive tumor microenvironment.
Bone metastasis. TGF-β released from bone matrix during osteolysis stimulates cancer cell production of PTHrP, creating a “vicious cycle” of bone destruction and tumor growth ⁶.

no-mechanism — the molecular switch that converts TGF-β from tumor-suppressive to pro-metastatic in individual tumors is not fully understood; likely involves loss of SMAD4, upregulation of non-canonical branches, and microenvironment context.

TGF-β in fibrosis

TGF-β1 is the master driver of pathological fibrosis across multiple organ systems:

IPF (Idiopathic Pulmonary Fibrosis): TGF-β1 drives myofibroblast differentiation (via SMAD3/SMA upregulation) and ECM production. TGF-β is a validated central mediator; anti-fibrotic drugs nintedanib and pirfenidone act partly by modulating TGF-β signaling.
Renal fibrosis, liver fibrosis (cirrhosis), cardiac fibrosis: Similar SMAD3-dependent ECM deposition mechanisms are operative.
Marfan syndrome: Mutations in FBN1 (fibrillin-1) dysregulate sequestration of latent TGF-β in the ECM, causing excess TGF-β activation — responsible for cardiovascular and skeletal manifestations. Losartan (angiotensin II blocker) reduces TGF-β signaling in Marfan mouse models.

The relationship between fibrosis, aging, and TGF-β is bidirectional: age-related increases in TGF-β promote tissue fibrosis, and fibrotic ECM remodeling further restricts stem cell niche function, amplifying stem-cell-exhaustion. unsourced — this bidirectional amplification loop has not been directly demonstrated in vivo; tag for follow-up.

Therapeutic angles

Small-molecule receptor inhibitors (ALK5/TβRI)

Compound	Target	Stage	Notes
Galunisertib (LY2157299)	ALK5 (TβRI)	Phase 2 (oncology)	Hepatocellular carcinoma, glioblastoma; intermittent dosing schedule to limit cardiac toxicity
Vactosertib (TEW-7197, EW-7197)	ALK4/5	Phase 1/2 (oncology)	Myelodysplastic syndrome, advanced solid tumors
SB505124	ALK4/5/7	Preclinical only	Research tool used in Yousef 2015 aging study

Anti-TGF-β antibodies and traps

Compound	Mechanism	Stage	Notes
Fresolimumab (GC1008)	Pan-TGF-β neutralizing Ab	Phase 2 (fibrosis, oncology)	IPF trial; skin fibrosis; cancer
Bintrafusp alfa (M7824)	Anti-PD-L1 × TGF-β trap bifunctional	Phase 2/3	Disappointing Phase 3 in NSCLC; PD-L1/TGF-β combination hypothesis not yet validated

Aging-focused therapeutic hypothesis

The demonstration that systemic TGF-β attenuation rejuvenates both muscle and neural stem cells in the same aged animal ⁵ raises the possibility of TGF-β inhibition as a multi-tissue rejuvenation strategy. Current blockers available clinically are cancer-focused with cardiac toxicity at continuous doses; an intermittent or niche-targeted dosing strategy would be needed for safe aging application. Open Targets lists TGF-β pathway targets as druggability tier 1 for multiple aging-related diseases. dose-response-unclear long-term-unknown

Cross-pathway connections

notch-pathway — Notch signaling in satellite cells antagonizes TGF-β-mediated quiescence; the Notch/TGF-β balance governs satellite cell activation vs. quiescence. Heterochronic parabiosis restores Notch signaling in aged muscle.
wnt-beta-catenin — Wnt and TGF-β signaling interact at the level of β-catenin (Wnt) and SMAD3 (TGF-β) co-occupying promoters of target genes; in satellite cells, Carlson and Conboy (2009) showed Wnt and TGF-β have distinct and overlapping roles in the systemic regulation of aged muscle ⁴.
bmp-signaling — BMP sub-family (SMAD1/5/8 downstream) opposes TGF-β/SMAD2/3 signaling in many contexts (e.g., bone formation); SMAD6 preferentially inhibits BMP signaling.
mtor — PI3K/AKT/mTOR is a non-canonical downstream branch of TGF-β; TGF-β can activate mTORC1 in some contexts, while mTOR inhibition can dampen pro-fibrotic TGF-β responses.
pi3k-akt-pathway — Direct non-canonical TGF-β effector; AKT activation downstream of TGF-β promotes cell survival and EMT.
nf-kb — TGF-β and NF-κB signaling intersect in inflammatory and oncogenic contexts; SMAD7 can activate NF-κB.
p53-pathway — p53 co-operates with SMAD2/3 to drive apoptosis in response to TGF-β; loss of p53 can shift TGF-β response toward pro-survival.

Limitations and gaps

#gap/needs-human-replication — Satellite cell and neurogenic rejuvenation by TGF-β inhibition shown only in mice. No human pharmacological intervention trial.
#gap/dose-response-unclear — Safe and effective dose for aging applications unknown; existing inhibitors designed for oncology dosing.
#gap/long-term-unknown — Chronic TGF-β inhibition carries fibrosis, auto-immune, and developmental risks; no long-term safety data in healthy aging context.
#gap/contradictory-evidence — GDF11 biology (a TGF-β superfamily member) is contested; see gdf11 for dispute details.
#gap/no-mechanism — Precise molecular mechanism by which SMAD3 hyperactivation is maintained in aged satellite cell niches (vs. ligand-level vs. receptor-level vs. downstream changes) not fully resolved.
#gap/needs-replication — The “dual rejuvenation” (muscle + brain) claim from a single pharmacological study ⁵ requires independent replication.

Footnotes

doi:10.1038/nature02006 · Derynck R & Zhang YE · Nature 2003 · review · n=N/A · model: biochemical/structural synthesis of TGF-β SMAD-dependent and SMAD-independent branches · 5,275 citations; locally available ↩ ↩² ↩³ ↩⁴
doi:10.1038/nature03260 · Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA · Nature 2005 · in-vivo · n= ~20 parabiotic pairs (heterochronic and isochronic) · model: C57BL/6 mice; satellite cell activation, liver regeneration, Notch signaling · 2,197 citations; locally available ↩
doi:10.1038/nature07034 · Carlson ME, Hsu M, Conboy IM · Nature 2008 · in-vivo + in-vitro · model: aged C57BL/6 muscle satellite cells + human satellite cells · pSMAD3-Notch imbalance drives CDK inhibitor (p15/p16/p21/p27) induction in old satellite cells; ALK5 inhibitor rescues activation in vivo · NOTE: correct DOI is 10.1038/nature07034; the alternate 10.1038/nature06849 is an unrelated neuroscience paper. See also smad2-smad3 ↩
doi:10.1111/j.1474-9726.2009.00517.x · Carlson ME, Conboy MJ, Hsu M, et al. · Aging Cell 2009 · in-vivo · model: aged mouse skeletal muscle; satellite cell activation assays; TGF-β/pSMAD3 quantification in aged vs young niches; pharmacological TβR inhibition restores satellite cell proliferation · 227 citations; archive: pending download ↩ ↩²
doi:10.18632/oncotarget.3851 · Yousef H, Conboy MJ, Morgenthaler A, et al. · Oncotarget 2015 · in-vivo · model: aged C57BL/6 mice; SB505124 (ALK4/5/7 inhibitor) systemic treatment; primary endpoints: BrdU+ hippocampal neural precursor cells, satellite cell activation; simultaneous dual-tissue rejuvenation reported · 116 citations; archive: pending download ↩ ↩² ↩³
doi:10.1016/j.cell.2008.07.001 · Massagué J · Cell 2008 · review · model: synthesis of human cancer genetics and mouse models · dual tumor-suppressor/pro-metastatic biology; SMAD4 loss in pancreatic cancer; immune evasion mechanisms · 3,825 citations; archive: pending download ↩ ↩²

🧬 Aging Wiki

Explorer

tgf-beta